Back to Search
Start Over
Oral Factor Xa Inhibitors for Venous Thromboembolism Prevention in Major Orthopedic Surgery: A Review
- Source :
- Pathophysiology of Haemostasis and Thrombosis. 36:217-226
- Publication Year :
- 2007
- Publisher :
- S. Karger AG, 2007.
-
Abstract
- Venous thromboembolism (VTE), which includes deep vein thrombosis and pulmonary embolism, is a major cause of morbidity and mortality in patients undergoing major orthopedic surgery, and routine thromboprophylaxis has been the standard of care over the last 20 years. Currently available options for the prevention of VTE in major orthopedic surgery include low-molecular-weight heparins, vitamin K antagonists and, more recently, the synthetic pentasaccharide fondaparinux. Although effective, these drugs have several limitations, and new oral antithrombotics offering predictable, effective and safe anticoagulation are strongly needed. This overview focuses on the most advanced oral direct inhibitors of factor Xa, rivaroxaban, apixaban, LY517717, YM150 and betrixaban. Specifically, the results of phase II and III studies and the designs of ongoing clinical trials in patients undergoing elective hip and knee replacement are reviewed.
- Subjects :
- medicine.medical_specialty
medicine.drug_mechanism_of_action
Premedication
Deep vein
Factor Xa Inhibitor
Administration, Oral
Physiology (medical)
medicine
Humans
Orthopedic Procedures
In patient
cardiovascular diseases
Enzyme Inhibitors
business.industry
Venous Thromboembolism
Hematology
medicine.disease
Thrombosis
Pulmonary embolism
Surgery
Treatment Outcome
medicine.anatomical_structure
Anesthesia
Orthopedic surgery
business
Venous thromboembolism
Factor Xa Inhibitors
Subjects
Details
- ISSN :
- 14248840 and 14248832
- Volume :
- 36
- Database :
- OpenAIRE
- Journal :
- Pathophysiology of Haemostasis and Thrombosis
- Accession number :
- edsair.doi.dedup.....4ad04ee725cf581a6f8c0213323e39e1